A Phase 2 interventional study of SHR0302 and Placebo in Ulcerative Colitis, sponsored by Reistone Biopharma Company Limited. Completed at 67 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.
Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 57th largest by enrollment of the 135 interventional ones that give a count, is one of 13 that started in 2019, is one of 34 in phase 2, and was the 38th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:
Accro Bioscience (Suzhou) Limited · Sites in China
Ages 18–75
Nanjing Immunophage Biotech Co., Ltd · Sites in China
Ages 18–70
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
Innatus Therapeutics (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 37 · Phase 4 11
First in 2009; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 120 across the 135 interventional studies, 176 across the 48 observational. Of the 58 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 183 have an industry lead sponsor. The 10 most frequent:
This study is registered under Reistone Biopharma Company Limited, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Reistone Biopharma Company Limited is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 5 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
26 of the studies in Colitis, Ulcerative with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
Add all 26 to your calendar (.ics) → With an account.
Among the 183 studies in Colitis, Ulcerative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study is a randomized, double-blind,placebo-controlled, multicenter phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active ulcerative colitis. The study aims to evaluate the optimal dose of SHR0302 and time needed to induce clinical response in active ulcerative colitis patients.
This is an 8+8 weeks study, in which participants who complete the first 8 weeks treatment phase, will have the option to enter a blinded active arms 8-week extension phase. Early withdrawn subjects during the first treatment phase can not enter the extension phase. The total duration of the study participation, including extension and follow-up, will be approximately 18 weeks.
SHR0302 is a Janus kinase 1(JAK1) inhibitor, capable of blocking Janus kinase-signal transducer and activator of transcription (JAK-STATs) pathway and controlling inflammation. Therefore it has the potential to be a treatment for ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized in this arm will receive SHR0302 8mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 8mg QD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Drug: SHR0302
Participants randomized in this arm will receive SHR0302 4mg BD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg BD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Drug: SHR0302
Participants randomized in this arm will receive SHR0302 4mg QD for the treatment phase. All participants that had completed the 8-week treatment phase (non-responders or responders) had the option to enter a blinded 8-week extension phase to continue to receive SHR0302 4mg QD. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
Drug: SHR0302
Participants randomized in this arm will receive the placebo until week 8, and then will be re-randomized into one of the 3 active arms ( 4mg QD, 4mg BD, 8mg QD of SHR0302) in a 1:1:1 allocation ratio until the end of the study at week 16. Those who had completed the first 8-week of the treatment phase, but decided not to enter into the extension phase were also required to attend the 2-week follow-up visit. Participants who immaturely withdrew during the first treatment phase could not enter the extension phase. SHR0302: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor). Placebos: Placebo Oral Tablet
Drug: SHR0302 · Drug: Placebo
The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
Also known as: Ivarmacitinib
Placebo Oral Tablet
The Percentage of Subject Achieve Clinical Response at Week 8
Clinical response is defined as a decrease from baseline in a 9-point modified Mayo score of at least 2 points and at least 30%, with an accompanying reduction in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1. The 9-point modified Mayo score is the Mayo score excluding the Physician Global Assessment sub-score, hence the maximum is 9 points and the minimum is 0 point, includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosio
Time frame: Week 8
The Percentage of Subjects Achieve Clinical Remission
Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects who achieve clinical remission per 9-point modified Mayo score at week 8, where stool frequency subscore ≤ 1, rectal bleeding subscore of 0, and endoscopic subscore ≤ 1. 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3. = Severe disease (spontaneous bleeding, ulceration)
Time frame: Week 8
The Percentage of Subjects Achieve Clinical Remission at Week 8
Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects achieve clinical remission at week 8 as per a total Mayo score of 2 points or lower ≤2, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular patt
Time frame: Week 8
The Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 8
Endoscopic remission was defined by Mayo endoscopic subscore ≤ 1 point. Mayo endoscopic subscore defines score 0 as normal or inactive disease, score 1 as mild disease (erythema, decreased vascular pattern, mild friability); score 2 as moderate disease (marked erythema, absent vascular pattern, friability, erosions); score 3 as severe disease (spontaneous bleeding, ulceration).
Time frame: Week 8
| Milestone | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| Started | 41 | 41 | 41 | 41 |
| Completed | 41 | 41 | 41 | 41 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| Started | 47 | 49 | 48 | 0 |
| Completed | 47 | 49 | 48 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
Clinical response is defined as a decrease from baseline in a 9-point modified Mayo score of at least 2 points and at least 30%, with an accompanying reduction in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1. The 9-point modified Mayo score is the Mayo score excluding the Physician Global Assessment sub-score, hence the maximum is 9 points and the minimum is 0 point, includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosio
| percentage of participants | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| The Percentage of Subject Achieve Clinical Response at Week 8 | 46.3 | 46.3 | 43.9 | 26.8 |
Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects who achieve clinical remission per 9-point modified Mayo score at week 8, where stool frequency subscore ≤ 1, rectal bleeding subscore of 0, and endoscopic subscore ≤ 1. 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 3. = Severe disease (spontaneous bleeding, ulceration)
| percentage of participants | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| The Percentage of Subjects Achieve Clinical Remission | 22.0 | 24.4 | 24.4 | 4.9 |
Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual sub-score exceeding 1 point. The percentage of subjects achieve clinical remission at week 8 as per a total Mayo score of 2 points or lower ≤2, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The 9-point modified Mayo score includes: Stool Frequency 0 = Normal 1. = 1-2 stools/day more than normal 2. = 3-4 stools/day more than normal 3. = 5 or more stools/day than normal Rectal bleeding 0 = None 1. = Visible blood with stool less than half the time 2. = Visible blood with stool half of the time or more 3. = Passing blood alone Mucosal appearance at endoscopy 0 = Normal or inactive disease 1. = Mild disease (erythema, decreased vascular pattern, mild friability 2. = Moderate disease (marked erythema, absent vascular patt
| percentage of participants | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| The Percentage of Subjects Achieve Clinical Remission at Week 8 | 14.6 | 17.1 | 17.1 | 2.4 |
Endoscopic remission was defined by Mayo endoscopic subscore ≤ 1 point. Mayo endoscopic subscore defines score 0 as normal or inactive disease, score 1 as mild disease (erythema, decreased vascular pattern, mild friability); score 2 as moderate disease (marked erythema, absent vascular pattern, friability, erosions); score 3 as severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo |
|---|---|---|---|---|
| The Percentage of Subjects Achieve Endoscopic Remission (Mucosal Healing) at Week 8 | 26.8 | 29.3 | 36.6 | 14.6 |
Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase-SHR0302 8mg QD | 0/41 (0%) | 2/41 (4.9%) | 13/41 (31.7%) |
| Treatment Phase-SHR0302 4mg BD | 0/41 (0%) | 0/41 (0%) | 11/41 (26.8%) |
| Treatment Phase-SHR0302 4mg QD | 0/41 (0%) | 2/41 (4.9%) | 12/41 (29.3%) |
| Treatment Phase-Placebo | 0/41 (0%) | 2/41 (4.9%) | 7/41 (17.1%) |
| Extension Phase-SHR0302 8mg QD → SHR0302 8mg QD | 0/36 (0%) | 1/36 (2.8%) | 13/36 (36.1%) |
| Extension Phase-SHR0302 4mg BD → SHR0302 4mg BD | 0/39 (0%) | 0/39 (0%) | 8/39 (20.5%) |
| Extension Phase-SHR0302 4mg QD → SHR0302 4mg QD | 0/35 (0%) | 0/35 (0%) | 11/35 (31.4%) |
| Extension Phase-placebo → SHR0302 8mg QD | 0/11 (0%) | 1/11 (9.1%) | 5/11 (45.5%) |
| Extension Phase-placebo → SHR0302 4mg BD | 0/10 (0%) | 1/10 (10%) | 5/10 (50%) |
| Extension Phase-placebo → SHR0302 4mg QD | 0/13 (0%) | 0/13 (0%) | 5/13 (38.5%) |
| Event | Treatment Phase-SHR0302 8mg QD | Treatment Phase-SHR0302 4mg BD | Treatment Phase-SHR0302 4mg QD | Treatment Phase-Placebo | Extension Phase-SHR0302 8mg QD → SHR0302 8mg QD | Extension Phase-SHR0302 4mg BD → SHR0302 4mg BD | Extension Phase-SHR0302 4mg QD → SHR0302 4mg QD | Extension Phase-placebo → SHR0302 8mg QD | Extension Phase-placebo → SHR0302 4mg BD | Extension Phase-placebo → SHR0302 4mg QD |
|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/41 | 0/41 | 2/41 | 1/41 | 1/36 | 0/39 | 0/35 | 1/11 | 1/10 | 0/13 |
| Anal abscessInfections and infestations | 0/41 | 0/41 | 0/41 | 1/41 | 0/36 | 0/39 | 0/35 | 0/11 | 0/10 | 0/13 |
| Cytomegalovirus infectionInfections and infestations | 1/41 | 0/41 | 0/41 | 0/41 | 0/36 | 0/39 | 0/35 | 0/11 | 0/10 | 0/13 |
| Liver abscessInfections and infestations | 0/41 | 0/41 | 0/41 | 1/41 | 0/36 | 0/39 | 0/35 | 0/11 | 0/10 | 0/13 |
| SynovitisMusculoskeletal and connective tissue disorders | 1/41 | 0/41 | 0/41 | 0/41 | 0/36 | 0/39 | 0/35 | 0/11 | 0/10 | 0/13 |
| Event | Treatment Phase-SHR0302 8mg QD | Treatment Phase-SHR0302 4mg BD | Treatment Phase-SHR0302 4mg QD | Treatment Phase-Placebo | Extension Phase-SHR0302 8mg QD → SHR0302 8mg QD | Extension Phase-SHR0302 4mg BD → SHR0302 4mg BD | Extension Phase-SHR0302 4mg QD → SHR0302 4mg QD | Extension Phase-placebo → SHR0302 8mg QD | Extension Phase-placebo → SHR0302 4mg BD | Extension Phase-placebo → SHR0302 4mg QD |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/41 | 5/41 | 1/41 | 1/41 | 0/36 | 2/39 | 1/35 | 0/11 | 2/10 | 0/13 |
| White blood cell count decreasedInvestigations | 2/41 | 0/41 | 1/41 | 0/41 | 4/36 | 0/39 | 1/35 | 0/11 | 1/10 | 0/13 |
| LeukocytosisBlood and lymphatic system disorders | 0/41 | 1/41 | 1/41 | 0/41 | 0/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| Sinus bradycardiaCardiac disorders | 0/41 | 0/41 | 0/41 | 0/41 | 1/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| FolliculitisInfections and infestations | 0/41 | 0/41 | 0/41 | 0/41 | 1/36 | 1/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| Gastrointestinal infectionInfections and infestations | 0/41 | 0/41 | 0/41 | 0/41 | 1/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| InfluenzaInfections and infestations | 0/41 | 0/41 | 0/41 | 0/41 | 0/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| Alanine aminotransferase increasedInvestigations | 1/41 | 0/41 | 2/41 | 1/41 | 0/36 | 0/39 | 1/35 | 1/11 | 1/10 | 0/13 |
| Bilirubin conjugated increasedInvestigations | 0/41 | 0/41 | 0/41 | 0/41 | 1/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| Blood bilirubin increasedInvestigations | 0/41 | 0/41 | 0/41 | 0/41 | 2/36 | 0/39 | 0/35 | 0/11 | 1/10 | 0/13 |
| Age, Continuous(years) | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 39.6 ± 13.3 | 40.3 ± 12.3 | 39.6 ± 10.0 | 42.7 ± 12.9 | 40.5 ± 12.2 |
| Sex: Female, Male(Participants) | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Female | 14 | 15 | 13 | 22 | 64 |
| Male | 27 | 26 | 28 | 19 | 100 |
| Race (NIH/OMB)(Participants) | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 29 | 25 | 25 | 24 | 103 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 12 | 16 | 16 | 17 | 61 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Time since initial primary diagnosis(years) | SHR0302 8mg QD | SHR0302 4mg BD | SHR0302 4mg QD | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 5.05 ± 4.16 | 5.62 ± 5.62 | 5.17 ± 5.17 | 5.77 ± 5.19 | 5.40 ± 5.03 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Nov 2020, 19 months.
Results were first posted in Nov 2022, 1 year 11 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 19 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivarmacitinib
Reistone Biopharma Company Limited →